- |||||||||| INVAC-1 / Invectys
Journal: Building on the promise of cancer vaccines for solid tumors. (Pubmed Central) - Oct 2, 2020
It induced CD8+ and CD4+ T cell responses and reduced circulating regulatory T cells. The findings support further development, especially in combination with vaccine adjuvants, plus therapies to increase immune infiltrates into solid tumor metastases.
- |||||||||| INVAC-1 / Invectys
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jul 8, 2020
P2, N=26, Terminated,
The findings support further development, especially in combination with vaccine adjuvants, plus therapies to increase immune infiltrates into solid tumor metastases. N=90 --> 26 | Trial completion date: Mar 2022 --> Jun 2020 | Recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Jun 2020; sponsor decision
- |||||||||| INVAC-1 / Invectys
Trial completion, Trial completion date, Metastases: INVAC-1 Anti-Cancer hTERT DNA Immunotherapy (clinicaltrials.gov) - Feb 26, 2019
P1, N=26, Completed,
These findings validate the MV-TERT vector to boost cell-mediated responses following DNA priming in humans. Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jun 2018
- |||||||||| INVAC-1 / Invectys
Enrollment closed, Trial primary completion date, IO biomarker, Metastases: INVAC-1 Anti-Cancer hTERT DNA Immunotherapy (clinicaltrials.gov) - Feb 28, 2018
P1, N=26, Active, not recruiting,
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Feb 2018
- |||||||||| INVAC-1 / Invectys
Enrollment open, Enrollment change, Trial primary completion date, IO biomarker, Metastases: INVAC-1 Anti-Cancer hTERT DNA Immunotherapy (clinicaltrials.gov) - Mar 3, 2017
P1, N=26, Recruiting,
Initiation date: Dec 2017 --> May 2018 Active, not recruiting --> Recruiting | N=20 --> 26 | Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| INVAC-1 / Invectys
Enrollment closed, Trial primary completion date, IO biomarker, Metastases: INVAC-1 Anti-Cancer hTERT DNA Immunotherapy (clinicaltrials.gov) - Sep 7, 2016
P1, N=20, Active, not recruiting,
Active, not recruiting --> Recruiting | N=20 --> 26 | Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Dec 2016
- |||||||||| INVAC-1 / Invectys
Enrollment change, IO biomarker, Metastases: INVAC-1 Anti-Cancer hTERT DNA Immunotherapy (clinicaltrials.gov) - May 10, 2016
P1, N=18, Recruiting,
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Dec 2016 N=27 --> 18
- |||||||||| INVAC-1 / Invectys
Trial primary completion date, IO biomarker, Metastases: INVAC-1 Anti-Cancer hTERT DNA Immunotherapy (clinicaltrials.gov) - Aug 25, 2015
P1, N=27, Recruiting,
N=27 --> 18 Trial primary completion date: Jan 2016 --> Jun 2016
- |||||||||| INVAC-1 / Invectys
Enrollment open, IO biomarker, Metastases: INVAC-1 Anti-Cancer hTERT DNA Immunotherapy (clinicaltrials.gov) - Dec 26, 2014
P1, N=27, Recruiting,
Trial primary completion date: Jan 2016 --> Jun 2016 Not yet recruiting --> Recruiting
|
